The United Kingdom and the United States have reached a key trade agreement that will ensure zero import taxes on UK medicine exports entering the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to raise spending on medicines through the public health system. This move secures that tariffs on these vital goods will remain at zero for a period of three years.
This deal follows recent threats to significantly raise tariffs on branded pharmaceutical imports, with potential rates floated reaching 100%.
"This agreement with the UK reinforces the international landscape for innovative medicines and introduces long-overdue fairness to U.S.–U.K. medicine commerce," a statement said.
Commercial Importance
Medicines are one of the the United Kingdom's largest goods shipped to the US, which is by far the primary buyer for major companies like GSK and AstraZeneca.
Statistics reveal that in the year to the end of the third quarter, the UK shipped medicines valued at over eleven billion pounds to the US. This value made up nearly one-fifth of British export trade in that timeframe.
"This deal secures employment, stimulates capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," a minister stated.
Specific UK Commitments
The agreement entails several key changes from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to double overall NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Payback Limit: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Last year, rebates were more than twenty percent.
Broader Context
The pact comes amid a protracted row between the drug companies and the ministers over drug pricing and NHS adoption.
This friction were heightened by assertions that American consumers were paying significantly more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or scrapped, while major expansions have been announced toward American operations.
The Science Minister stated that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had decreased as a share of its resources over the last ten years.
